MissionIR Articles
-
SPAC Merger Fires Boosters for 180 Life Sciences’ Exploration in Unmet Medical Needs of Anti-inflammatories Space
Biotechnology company 180 Life Sciences has launched a variety of advanced clinical and preclinical-stage efforts to develop novel anti-inflammatory treatments for patients with chronic illnesses A planned merger with 180 Life Sciences advanced under a…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. Featured in NNW Editorial Discussing Big Pharma Acquisitions
180 Life Sciences Corp. was discussed prominently in an editorial published by NetworkNewsWire (“NNW”), one of 50-plus brands in the InvestorBrandNetwork (“IBN”). The editorial, titled “Banking on the Next Blockbuster Drug,” discusses the significant amounts of time…
-
180 Life Sciences Corp. Expands IP Portfolio with EU, U.S., and Chinese Patents
The company’s patent portfolio includes its own intellectual property and exclusive worldwide licenses, including in the U.S., Canada, Europe, Australia, Hong Kong, and China 180 Life Sciences is in the final stages of its merger…
-
180 Life Sciences Corp. Bringing Hope to Those Afflicted by Dupuytren’s Disease and Other Inflammatory Conditions
180 Life Sciences is a clinical-stage biotechnology company developing anti-tumor necrosis factor (“TNF”) therapies to treat a variety of inflammatory conditions. Phase 2b/3 clinical trials on fibrosis and inflammation-causing TNF irregularity are currently underway with…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. Announces New Board Appointments
KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that previously entered a definitive agreement to acquire 180 Life Sciences, a…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. Setting the Stage for Success in Bringing Novel Products to Market
180 Life Sciences, a clinical-stage biotechnology company, is focused on research to solve one of the world’s most significant drivers of disease – inflammation. The company currently has three programs for the development of novel…
-
MissionIRNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials
180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF…
-
180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021
Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used…
-
KBL Merger Corp. IV (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) Fulfilling IPO Goal Through Merger With 180 Life Sciences Corp.
KBL Merger Corp. IV is set to finalize the acquisition of 180 Life Sciences Corp. during Q4 2020 180 Life Sciences Corp. has several ongoing programs at different stages of development, with the leading candidate…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Completes Participation In U.S. Army TiC 2.0 Autonomous Breach Event
- MissionIRNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Schedules Q4 And Full-Year 2025 Financial Results Release
- MissionIRNewsBreaks – Innovation Beverage Group Limited (NASDAQ: IBG) Closes $6 Million Public Offering
- MissionIRNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS) Expands AI Advisory Board To Support ai6 Labs Growth
- Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy